Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
https://doi.org/10.14341/DM12768
Abstract
Sulfonylureas are widely prescribed all over the world, mainly because of their high effectiveness. At the same time, the heterogeneity of the group is obvious, primarily in relation to the effect of drugs on the risk of developing hypoglycemic events. The review presents the results of new studies, including «Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes» and results of a model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes, confirming the higher efficacy of modified release gliclazide (gliclazide MB) compared to DPP-4, as well as a low risk of hypoglycemic conditions. The results of recent studies, as well as the results of the ADVANCE and ADVANCE-ON studies, suggest that gliclazide MB is safe to use as a second-line drug, especially in patients with chronic kidney disease.
About the Authors
I. V. Kononenko
Endocrinology Research Centre
Russian Federation
Russian Federation
Irina V. Kononenko, MD, PhD, leading research associate
11 Dm. Ulyanova street, 117036 Moscow
eLibrary SPIN 6528-7986
O. M. Smirnova
Endocrinology Research Centre
Russian Federation
Russian Federation
Olga M. Smirnova, MD, PhD, Professor, chief research associate
eLibrary SPIN: 9742-8875
Moscow
References
1. Bibliography:
2. Diabetes mellitus in the Russian Federation: prevalence, morbidity, mortality, parameters of carbohydrate metabolism and the structure of antihyperglycemic therapy according to the Federal Register of Diabetes Mellitus, status 2017 I.I. Dedov, M.V. Shestakova, O. K. Vikulova *, A.V. Zheleznyakova, M.A. Isakov. Diabetes mellitus 2018; 21 (3): 143-159
3. Brown J. B., Conner C., Nichols G. Secondary Failure of Glycemic Control for Patients Adding Thiazolidinedione or Sulfonylurea Therapy to a Metformin Regimen. Diabetes Care 33: 501-506, 2010
4. Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
5. Garber A, Abrahamson M, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Type 2 Diabetes Management Algorithm 2016. Endocr Pract. 2016; 22: 84-113.
6. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013 Nov; 36 (11): 3411-7. doi: 10.2337 / dc13-0331.
7. Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabet Med 2015; 32: 407-413.
8. Cook MN, Girman CJ, Stein PP, Alexander CM: Initial monotherapy with either metformin or sulfonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007, 24: 350-358.
9. Sanjoy K Paul, Kerenaftali Klein, Brian L Thorsted, Michael L Wolden, Kamlesh Khunti. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015 Aug 7; 14: 100. doi: 10.1186 / s12933-015-0260-x.
10. Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-year follow-up of intensive glycemic control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-1589.
11. "Algorithms of specialized medical care for patients with diabetes mellitus" edited by I.I. Dedov, M, V. Shestakova, A. Yu. Mayorov, 9th edition, 2019.
12. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes — 2021. American Diabetes Association Diabetes Care 2021 Jan; 44 (Supplement 1): S111-S124.https: //doi.org/10.2337/dc21-S009
13. Datta-Nemdharry P, Thomson A, Beynon J, Donegan K. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales. Pharmacoepidemiol Drug Saf 2017; 26: 127-35.
14. Khunti K, Godec T. R., Medina J. et. al. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. Diabetes Obes Metab. 2018; 20: 389-399.
15. Francesco Zaccardi, Emmanuelle Jacquot ,, Viviana Cortese, Freya Tyrer MSc, Samuel Seidu, Melanie J. Davies, Kamlesh Khunti. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 1-10 DOI: 10.1111 / dom.1416.
16. Alan Maloney, Julio Rosenstock, Vivian Fonseca. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clinical Pharmacology & therapeutics | Volume 105 Number 5 | MAY 2019.
17. Al Sifri S., Basiounny A., Echtay A., Al Omari M. et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomized trial // Int. J. Clin. Pract. 2011. Vol. 65. P. 1132-1140. 34.
18. Aravind S.R., Tayeb K.A., Ismail S.B. et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study // Curr. Med. Res. Opin. 2011. Vol. 27. P. 1237-1242. doi: 10.1185 / 03007995.2011.578245.
19. Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017; 126: 303-16.
20. Nicolucci A, Charbonnel B, Gomes MB, et al. Treatment patterns and associated factors in 14,668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study program. Diabetes Obes Metab. 2019; 21: 2474-2485. https://doi.org/10.1111/dom.13830.
21. Matthews D.R. ADVANCE. Diabetes Obes Metab. 2020; 22 (suppl 2): 3-4. DOI: https://doi.org/10.1111/dom.14014.
22. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118–20.
23. Instructions for medical use of the drughttp://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c7ca665a-12a9-44d6-a6f5-672069650494&t=. Ссылка активна на 18.05.2021
Supplementary files
|
|
1. Figure 1. The most frequently prescribed 2nd line drugs according to the data of a retrospective cohort study with the analysis of a database of patients from the UK and Germany (n = 10 256) [14, 15]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(144KB)
|
Indexing metadata ▾ | |
|
|
2. Figure 2. Scheme of the formation of patient groups in the study "Comparative efficacy of gliclazide MB and sitagliptin in real practice as second-line drugs after monotherapy with metformin in patients with uncontrolled type 2 diabetes." | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(293KB)
|
Indexing metadata ▾ | |
Review
For citations:
Kononenko I.V., Smirnova O.M. Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies. Diabetes mellitus. 2021;24(4):350-356. (In Russ.) https://doi.org/10.14341/DM12768
Views:
6640
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
